Allergy Nasal Spray Generics Need Flexibility On Device Design, GPhA Says
Executive Summary
The Generic Pharmaceutical Association is requesting that FDA approve generic antihistamine nasal sprays that are different in design from the reference drug's container closure system
You may also be interested in...
Allergy Bioequivalence No “Day In The Park”; FDA Seeks Only One Study
FDA is recommending one traditional study design for demonstrating bioequivalence in NDAs and ANDAs for nasal aerosols and sprays seeking a seasonal allergic rhinitis indication
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials